WO2008125903A3 - Method of inhibiting an undesired immune response - Google Patents

Method of inhibiting an undesired immune response Download PDF

Info

Publication number
WO2008125903A3
WO2008125903A3 PCT/IB2007/004414 IB2007004414W WO2008125903A3 WO 2008125903 A3 WO2008125903 A3 WO 2008125903A3 IB 2007004414 W IB2007004414 W IB 2007004414W WO 2008125903 A3 WO2008125903 A3 WO 2008125903A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune response
therapeutic agent
subject
inhibiting
auto
Prior art date
Application number
PCT/IB2007/004414
Other languages
French (fr)
Other versions
WO2008125903A2 (en
Inventor
Yehuda Chowers
Simon Bar-Meir
Shomron Ben-Horin
Original Assignee
Chaim Sheba Medical Ct
Yehuda Chowers
Simon Bar-Meir
Shomron Ben-Horin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chaim Sheba Medical Ct, Yehuda Chowers, Simon Bar-Meir, Shomron Ben-Horin filed Critical Chaim Sheba Medical Ct
Publication of WO2008125903A2 publication Critical patent/WO2008125903A2/en
Publication of WO2008125903A3 publication Critical patent/WO2008125903A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

The invention provides a method of suppressing an immune response to a therapeutic agent, the method comprising administering to a subject in need thereof a combination of a purified first therapeutic agent and a second therapeutic agent, wherein the combined dose of the first and second therapeutic agents suppresses an immune response to the first therapeutic agent in the subject. The invention also provides a method of suppressing an immune response to auto- antigens, the method comprising administering to a subject in need thereof a combination of an auto antigen or a mixture of auto-antigens and a second therapeutic agent, wherein the combined dose of the first and second therapeutic agents suppresses an immune response to auto-antigens in the subject.
PCT/IB2007/004414 2006-12-12 2007-12-12 Method of inhibiting an undesired immune response WO2008125903A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87468706P 2006-12-12 2006-12-12
US60/874,687 2006-12-12

Publications (2)

Publication Number Publication Date
WO2008125903A2 WO2008125903A2 (en) 2008-10-23
WO2008125903A3 true WO2008125903A3 (en) 2009-07-16

Family

ID=39864416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004414 WO2008125903A2 (en) 2006-12-12 2007-12-12 Method of inhibiting an undesired immune response

Country Status (1)

Country Link
WO (1) WO2008125903A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085407A1 (en) * 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
WO2011032204A1 (en) * 2009-09-15 2011-03-24 Csl Limited Treatment of neurological conditions
WO2011135024A1 (en) * 2010-04-29 2011-11-03 Biomedical Diagnostics Sa Methods for detecting antibodies
CA3130348A1 (en) * 2019-03-14 2020-09-17 Motti HAKIM A method for immunosuppression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006451A1 (en) * 1987-02-24 1988-09-07 Xoma Corporation Immunosuppression in immunotoxin based human therapy
US20040009906A1 (en) * 2002-05-06 2004-01-15 Kakkis Emil D. Induction of antigen specific immunologic tolerance
WO2005099776A2 (en) * 2004-04-01 2005-10-27 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
WO2006113308A1 (en) * 2005-04-15 2006-10-26 Genentech, Inc. Method for treating inflammatory bowel disease (ibd) by an anti-cd20 antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006451A1 (en) * 1987-02-24 1988-09-07 Xoma Corporation Immunosuppression in immunotoxin based human therapy
US20040009906A1 (en) * 2002-05-06 2004-01-15 Kakkis Emil D. Induction of antigen specific immunologic tolerance
WO2005099776A2 (en) * 2004-04-01 2005-10-27 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
WO2006113308A1 (en) * 2005-04-15 2006-10-26 Genentech, Inc. Method for treating inflammatory bowel disease (ibd) by an anti-cd20 antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAERT F ET AL: "INFLUENCE OF IMMUNOGENICITY ON THE LONG-TERM EFFICACY OF INFLIXIMAB IN CROHN'S DISEASE", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 7, 13 February 2003 (2003-02-13), pages 601 - 608, XP009037271, ISSN: 1533-4406 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2005 (2005-04-01), CARVALHO RYAN S ET AL: "6-thioguanine induced apoptosis: a putative immunosuppressive mechanism of action for 6-mercaptopurine in patients with Crohn's disease.", XP002519034, Database accession no. PREV200600209112 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2006 (2006-04-01), BEN-HORIN SHOMRON ET AL: "Activated lymphocytes, which are arrested from proliferation by 6-mereaptopurine, still maintain their viability and their pro-inflammatory effector functions: A novel mechanism for the delayed effect of anti-purines in IBD", XP002519035, Database accession no. PREV200600503812 *
GASTROENTEROLOGY, vol. 128, no. 4, Suppl. 2, April 2005 (2005-04-01), ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION/DIGEST IVE-DISEASE-WEEK; CHICAGO, IL, USA; MAY 14 -19, 2005, pages A12, ISSN: 0016-5085 *
GASTROENTEROLOGY, vol. 130, no. 4, Suppl. 2, April 2006 (2006-04-01), DIGESTIVE DISEASE WEEK MEETING/107TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; LOS ANGELES, CA, USA; MAY 19 24, 2006, pages A356, ISSN: 0016-5085 *
TRAVIS S.P.L. ET AL.: "European evidence based consensus on the diagnosis and management of Crohn's disease : current management.", GUT, vol. 55, no. Suppl.1, March 2006 (2006-03-01), pages I16- - I36, XP002519033 *

Also Published As

Publication number Publication date
WO2008125903A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
MX2007003907A (en) Therapeutic agents with decreased toxicity.
WO2006031878A3 (en) Imidazoquinoline compounds
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2007117996A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
UA103614C2 (en) Medicinal composition for treating hepatic cancer which comprises a kinase inhibitor. combined with glypican 3 antibody
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2004084950A3 (en) Cell targeting methods and compositions
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008039390A3 (en) Compositions and methods for chitosan enhanced immune response
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2007048027A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2009055076A3 (en) Methods and compositions for inhibition of immune responses and autoimmunity
WO2005107810A3 (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
WO2006091542A3 (en) Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
WO2006007671A3 (en) Therapeutically combinations
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873331

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07873331

Country of ref document: EP

Kind code of ref document: A2